Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

Inclusion Criteria

• •Males or female sex
• •≥18 years of age
• •Willingness to provide signed informed consent and comply with all protocol requirements
• •Histological confirmation of RCC with a clear cell component
• •2-10 sites of disease measuring ≥1.5 cm on contrast-enhanced CT and/or MRI imaging of the chest, abdomen and pelvis performed ≤60 days prior to the date of study enrollment
• •Screening clinical laboratory values as specified below:
• •* Serum bilirubin ≤ 1.5 times the upper limit of normal; for patients with known Gilbert's syndrome, ≤ 3 × ULN is permitted
• •* ALT ≤ 3 times the upper limits of normal
• •* AST ≤ 3 times the upper limits of normal
• •* Creatinine clearance ≥50 mL/min based on Cockcroft-Gault formula
• •* Absolute neutrophil count ≥ 1,500 /mm3
• •* Platelets ≥100,000/ mm3
• •* Hemoglobin ≥ 9.0 g/dL
• •* White blood cell count ≥ 2,000/ mm3